Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company which focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological, and autoimmune disorders. The company’s marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company’s research and development focuses on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.